Octocog alfa sucrose formulation - Bayer HealthCare

Drug Profile

Octocog alfa sucrose formulation - Bayer HealthCare

Alternative Names: BAY 81-8973; BAY-14-2222; Factor VIII sucrose formulation - Bayer; Helixate FS; Helixate NexGen; Iblias; Kogenate Bayer; Kogenate FS; Kogenate PF; Kogenate SF; Kovaltry; rFVIII FS

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; CSL Behring
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 29 Jun 2016 Launched for Haemophilia A in Japan (IV) before June 2016 (PMDA website)
  • 28 Mar 2016 Registered for Haemophilia A in Japan (IV) (PMDA website)
  • 17 Mar 2016 Registered for Haemophilia A (In children, In infants, In neonates, In adolescents, Prevention, In adults) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top